Palvella Therapeutics (NASDAQ:PVLA) Receives Consensus Rating of “Buy” from Analysts
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) has earned an average rating of “Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target […]
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) has earned an average rating of “Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target […]
